Medical knowledge Clinical knowledge (MK1) Knowledge of diagnostic testing and procedure (MK2) Scholarship (MK3) Fellows must demonstrate knowledge of established and evolving biomedical, clinical, epidemiologic, and social behavioral sciences, as ... CHEST, 14 hours ago
MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
Company News: Page (1) of 1 - 09/01/14 print page (September 01, 2014) LA JOLLA, Calif., Sept. 1, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ ...Tutorial Finder, 20 hours ago Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) Review Seeker, 1 week ago Treatments for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, 1 week ago Auspex Pharmaceuticals To Present At The 2014 Healthcare Conference BioSpace, 5 days ago
More from: Stock Nod, Stock Nod...and 35 other sources
Victoria Ulrich a , Eddy S. Konaniah b , Joachim Herz c , Robert D. Gerard d , Eunjeong Jung a , Ivan S. Yuhanna a , Mohamed Ahmed a , David Y. Hui b , Chieko Mineo a , 1 , and Philip W. Shaul a , 1 a Center for Pulmonary and Vascular ...PNAS, 2 hours ago
A woman in her 80s with hypertension and dyslipidemia was seen in the ED complaining of progressive dyspnea for 3 days. She was found to be tachypneic and hypoxemic and was admitted to the internal medicine service with a provisional diagnosis of ...CHEST, 14 hours ago Exercise is the best medicine for many patients Irish Independent, 1 week ago
Orphan designation: Humanised anti-alpha ν beta 6 monoclonal antibody, for the: Treatment of idiopathic pulmonary fibrosis
orphan designation (EU/3/14/1301) was granted by the European Commission to Biogen Idec Ltd, United Kingdom, for humanised anti-alpha ν beta 6 monoclonal antibody for the treatment of idiopathic pulmonary fibrosis. What is idiopathic pulmonary ...European Medicines Agency, 1 day ago Orphan designation: Riociguat, for the: Treatment of systemic sclerosis European Medicines Agency, 1 day ago
Comments - NEW YORK, NY Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2014. Copies ...AndhraNews.net, 1 day ago DAXOR : Announces Filing of Form N-CSR for June 30, 2014 4 Traders, 4 days ago
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
[September 01, 2014] (ENP Newswire Via Acquire Media NewsEdge) ENP Newswire - 01 September 2014 Release date- 29082014 - Berlin, - Bayer HealthCare and its development partner Janssen Research & Development, LLC announced today ...TMC Net, 1 day ago
MUNICH, Germany — First results from AMBITION, the large pulmonary arterial hypertension trial, will be presented at the European Respiratory Society (ERS) International Congress 2014 , which runs from September6 to 10. Congress chair Oliver ...General Medicine eJournal, 4 days ago
Bristol Myers Squibb : U.S. FDA Approves Eliquis apixaban for the Treatment of Deep Vein Thrombosis DVT and Pulmonary Embolism PE, and for the Reduction in the Risk of...
U.S. FDA Approves Eliquis apixaban for the Treatment of Deep Vein Thrombosis DVT and Pulmonary Embolism PE, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy By a News Reporter-Staff News Editor at Biotech Week ...4 Traders, 5 days ago Aspirin Reduces Blood Clot Risk; Prevents Heart Attack and Stroke International Business Times India, 1 week ago FDA OKs Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism Individual.com, 1 week ago
on your WebpageAdd Widget >Get your members hooked!